MARK L PERRY
CIK 1190270 · last filed 2024-06-26
MARK L PERRY is a corporate insider who has filed 53 SEC Form 4 insider transactions across 3 companies since 2008. The most recent filing, for NVDA, was dated Jun 26, 2024. Across all open-market trades the lifetime net is −$55.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.00M
3
53
-$55.13M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVDA | Director | 14,612 | $205.19 | $3.00M | -$51.09M | 30 | 2024-06-26 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | 0 | $68.49 | $0 | -$4.09M | 11 | 2022-10-06 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 27,708 | — | — | $50.0K | 9 | 2020-06-23 |
Recent Filings
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-26 | NVDA | — | — | $0 | EDGAR |
| 2024-04-03 | NVDA | Sell (S) | −7,000 | -$6.22M | EDGAR |
| 2024-02-27 | NVDA | Sell (S) | −15,000 | -$11.95M | EDGAR |
| 2023-06-27 | NVDA | Grant (A) | +650 | $0 | EDGAR |
| 2023-05-31 | NVDA | Gift (G) | — | $0 | EDGAR |
| 2023-02-28 | NVDA | Sell (S) | −20,000 | -$4.73M | EDGAR |
| 2022-10-06 | Global Blood Therapeutics, Inc. (GBT) Delisted | Disp (D) | −37,865 | $0 | EDGAR |
| 2022-06-16 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +3,600 | $0 | EDGAR |
| 2022-06-07 | NVDA | Grant (A) | +1,438 | $0 | EDGAR |
| 2022-03-21 | NVDA | Sell (S) | −16,716 | -$4.41M | EDGAR |